Cover Image
市場調查報告書

眼瞼炎:開發中產品分析

Blepharitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200931
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
眼瞼炎:開發中產品分析 Blepharitis - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 44 Pages
簡介

眼瞼炎是指眼皮發炎。一般是在皮膚上普遍存在的細菌過度繁殖,或是眼皮的皮脂腺堵塞等,都是眼臉炎發病的要因,但各種過敏症也有可能導致發病。瞼炎的症狀有眼睛流淚發紅,眼皮發癢,畏光等。主要的治療方法有抗生素和眼藥,類固醇眼藥、軟膏等。

本報告提供全球各國治療眼瞼炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要 (標的,作用機制,投藥途徑,許可證/產業強力體制等),最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

眼瞼炎概要

治療藥的開發

  • 眼瞼炎開發中產品:概要
  • 眼瞼炎開發中產品:比較分析

各企業開發中的眼瞼炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

眼瞼炎治療藥:開發中的產品一覽 (各企業)

眼瞼炎開發治療藥的企業

  • Allergan Plc
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • NicOx S.A.
  • Quorum Innovations LLC
  • 千壽製藥

眼瞼炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

眼瞼炎治療藥:開發暫停的產品

眼瞼炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8362IDB

Summary

Global Markets Direct's, 'Blepharitis - Pipeline Review, H2 2016', provides an overview of the Blepharitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Blepharitis
  • The report reviews pipeline therapeutics for Blepharitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects
  • The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Blepharitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Blepharitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Blepharitis Overview
  • Therapeutics Development
    • Pipeline Products for Blepharitis - Overview
  • Blepharitis - Therapeutics under Development by Companies
  • Blepharitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Blepharitis - Products under Development by Companies
  • Blepharitis - Companies Involved in Therapeutics Development
    • Allergan Plc
    • InSite Vision Incorporated
    • Kala Pharmaceuticals, Inc.
    • NicOx S.A.
    • Quorum Innovations LLC
    • Senju Pharmaceutical Co., Ltd.
  • Blepharitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGN-195263 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISV-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Blepharitis - Dormant Projects
  • Blepharitis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults
      • Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Blepharitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Blepharitis - Pipeline by Allergan Plc, H2 2016
  • Blepharitis - Pipeline by InSite Vision Incorporated, H2 2016
  • Blepharitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Blepharitis - Pipeline by NicOx S.A., H2 2016
  • Blepharitis - Pipeline by Quorum Innovations LLC, H2 2016
  • Blepharitis - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Blepharitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Blepharitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top